Bioquell HPV shown to be effective against MERS-CoV
A recent study from scientists at the University of Minnesota in collaboration with Bioquell demonstrates that HPV is effective against transmissible gastroenteritis coronavirus (TGEV)
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has emerged in the last few years in the Middle East, with cases now reported from most of the world. Like other respiratory viruses, it is likely to be spread by both contact and droplet routes. Therefore, careful attention is required for the disinfection of rooms used to care for patients with MERS-CoV.
One option is the use of hydrogen peroxide vapour (HPV), an automated room disinfection system that removes reliance on the operator to assure adequate distribution and contact time of the disinfectant.
A recent study from scientists at the University of Minnesota in collaboration with Bioquell demonstrates that HPV is effective against transmissible gastroenteritis coronavirus (TGEV), which is closely related to the SARS and MERS human coronaviruses and is therefore used as a surrogate for testing.
TGEV was dried on surfaces and exposed to HPV, which demonstrated a greater than 4-log reduction in the viability of the virus. In fact, no TGEV was viable after the process. This demonstrates that HPV is a viable option for the terminal disinfection of clinical areas used to care for patient with TGEV.
Commenting on the growing emergence, James Salkeld head of healthcare at Bioquell said: 'We recognise the global concern surrounding MERS-CoV and believe that Bioquell HPV provides a tool that could help to prevent transmission.'
